Medications | My Protocol

Medications

Peter Attia's prescription lipid therapy as stated in October 2023: Repatha twice monthly and Nexlizet, used to target apoB of 30–40 mg/dL. He separately reported stopping metformin in 2019 and stopping rapamycin 'for now' by October 2025 after mouth sores. No current dose is inferred for either stopped drug.

Reported protocol · For reference, not advice

Date of record:: 26 Oct 2025

Interventions

Medications

Evolocumab, PCSK9 inhibitorRepatha
twice monthly injection
genetic cardiovascular risk; targeting apoB of 30–40 mg/dL from a baseline of about 90–100
Details & sources
Milligrams not restated. "The twice monthly shot that I take", The Drive
Sources1
Bempedoic acid + ezetimibeNexlizet
same apoB target of 30–40 mg/dL; he reported no side effects for himself
Details & sources
Dose and frequency not stated. The Drive
Sources1
Rapamycin
Stopped · Date not stated
previously taken experimentally for longevity; stopped after mouth sores
Details & sources
Stopped 'for now' because of mouth sores, reported by 60 Minutes on 26 Oct 2025. No historical dose or cycle is shown because the available dose source was secondary.
Sources2
Metformin
Stopped · 2019
previously taken for longevity, not diabetes
Details & sources
Attia said in 2019 that he had stopped metformin after nine years of use. The month and day were not stated; a later restart is not established by this record.
Sources3

Sources

Original accounts behind this protocol. Numbers match the references in each intervention.

01The Drive #276: Peter answers questions on longevity, supplements, protein, fasting, apoB, statins, and more Repatha (evolocumab, PCSK9 inhibitor) · Nexlizet (bempedoic acid + ezetimibe)
02Dr. Peter Attia says enjoying a longer, healthier life requires serious training Rapamycin
03Metformin and exercise — déjà vu all over again? Metformin

Repatha and Nexlizet are from